Jingjing Yu
Affiliations: | 2007 | Biology | Rensselaer Polytechnic Institute, Troy, NY, United States |
Google:
"Jingjing Yu"Mean distance: (not calculated yet)
Parents
Sign in to add mentorRobert J. Linhardt | grad student | 2007 | RPI | |
((Understanding the Mechanism of Polyphenolic Inhibition on Human Vascular NADPH Oxidase)) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
McFeely SJ, Ritchie TK, Yu J, et al. (2020) Inhibitors of Organic Anion-Transporting Polypeptides 1B1 and 1B3: Clinical Relevance and Regulatory Perspective. Journal of Clinical Pharmacology |
Yu J, Ragueneau-Majlessi I. (2020) In vitro-to-in vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the U.S. Food and Drug Administration in 2018. Clinical and Translational Science |
Yu J, Petrie I, Ragueneau-Majlessi I. (2020) P87 - Main mechanisms of pharmacokinetic drug-drug interactions triggering label recommendations for drugs approved by the food and drug administration in 2018 Drug Metabolism and Pharmacokinetics. 35 |
McFeely SJ, Yu J, Zhao P, et al. (2019) Drug-Drug Interactions of Infectious Disease Treatments in Low Income Countries: A Neglected Topic? Clinical Pharmacology and Therapeutics |
McFeely SJ, Ritchie TK, Yu J, et al. (2019) Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3. Clinical and Translational Science |
Yu J, Petrie ID, Levy RH, et al. (2018) Mechanisms and Clinical Significance of Pharmacokinetic-based Drug-drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017. Drug Metabolism and Disposition: the Biological Fate of Chemicals |
Yu J, Zhou Z, Tay-Sontheimer J, et al. (2018) Risk of Clinically Relevant Pharmacokinetic-based Drug-drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016. Drug Metabolism and Disposition: the Biological Fate of Chemicals |
Yu J, Ragueneau-Majlessi I. (2018) Understanding the risk of clinically significant pharmacokinetic-based drug–drug interactions with drugs newly approved by the US FDA – A review of recent new drug applications (2013–2016) Drug Metabolism and Pharmacokinetics. 33 |
Yu J, Zhou Z, Tay-Sontheimer J, et al. (2017) Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Pre-clinical and Clinical Findings. Journal of Pharmaceutical Sciences |
Yu J, Zhou Z, Owens KH, et al. (2016) What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the U.S. FDA in 2015. Drug Metabolism and Disposition: the Biological Fate of Chemicals |